Document is current
Any future updates will be listed below
-
Authors
Mosenzon, Ofri https://orcid.org/0000-0002-5702-7584
Del Prato, Stefano
Schechter, Meir
Leiter, Lawrence A.
Ceriello, Antonio
DeFronzo, Ralph A.
Raz, Itamar
- License Information
-
More Information
Article History
Received: 29 January 2021
Accepted: 15 April 2021
First Online: 28 April 2021
Declarations
:
: Not applicable.
: Not applicable.
: OM declares advisory board membership from AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim; Speaker’s bureau honorarium from AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, and Jansen; and research grants from Novo Nordisk and AstraZeneca.SDP declares advisory board membership from Astra Zeneca; Boehringer Ingelheim; Eli Lilly and Co; GlaxoSmithKline; Merck & Co.; Novartis Pharmaceuticals; Novo Nordisk; sanofi; speaking commitments for Astra Zeneca; Boehringer Ingelheim; Eli Lilly and Co; Merck & Co.; Novartis Pharmaceuticals; Novo Nordisk; Sanofi, Takeda Pharmaceuticals; research support from Astra Zeneca; Boehringer Ingelheim.MS declares no conflict of interest.LAL has received research support from, has provided CME on behalf of, and/or has acted as an advisor to AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Lexicon, Novo Nordisk, Sanofi, and/or Servier.AC declares advisory board membership from BD, Eli Lilly, Mundipharma; speakers’ bureau honorarium from Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk, Roche Diagnostics; research grant from Mitsubishi.RAD declares Advisory Board: Astra Zeneca, Novo Nordisk, Janssen, Boehringer-Ingelheim, Intarcia, Poxel—Honorarium Research Support: Boehringer-Ingelheim, Astra Zeneca, Janssen, Merck—Research Grant—(Investigator) Speaker's Bureau: Novo-Nordisk, Astra Zeneca—Honorarium (Speaker).IR declares Advisory Board membership from AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, Inc, Sanofi; Consultant fees from AstraZeneca, Insuline Medical, Medial EarlySign Ltd, CamerEyes Ltd, Exscopia, Orgenesis Ltd, BOL Pharma, Glucome Ltd, DarioHealth, Diabot, Concenter BioPharma, CuraLife Ltd; Speaker’s Bureau honorarium from AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, Inc., Sanofi and Stock/Shareholder interests from Glucome Ltd, Orgenesis Ltd, DarioHealth, CamerEyes Ltd, Diabot, BOL Pharma.
